The primary reason cited for failure of new drug candidates during clinical trials is the lack of an appropriate pharmacokinetics profile. Lead compounds in drug discovery research should be selected based on the exhibition of an appropriate pharmacokinetics profile in order to achieve the desired pharmacological action and to minimize side effects during phase I clinical trials. It is therefore crucial to perform preclinical pharmacokinetics studies in addition to in vitro ADME (Absorption, Distribution, Metabolism and Excretion) profiling to determine valuable information necessary for the generation of plasma concentration versus time profiles. NoAb BioDiscoveries is a leading provider of premier drug discovery services that include preclinical pharmacokinetics studies conducted in vivo, in vitro ADME assays, gene expression profiling and bioanalytical services. Detailed information on these services is available at www.noabbiodiscoveries.com.
Preclinical pharmacokinetics studies are performed at the NoAb BioDiscoveries' research facility which is located in the heart of one of North America's key biotech hubs. The government approved vivarium houses small rodents including rats and mice for all preclinical pharmacokinetics studies. All specialized and standard protocols are skillfully performed by highly trained and experienced scientists in-house under strict guidelines. This means that you are assured of quality, efficiency and timeliness when it comes to your specific interest. The scientists have the capabilities to design the best strategies and protocols for any drug discovery needs according to customer specifications.
Fully conscious animals that have been appropriately catheterized for drug administration and sample collection are used for all preclinical pharmacokinetics studies. These studies are performed in carotid artery and jugular vein catheterized rats with intra-duodenal dosing, carotid artery, jugular vein and bile duct catheterized rats and guinea pigs and hepatoportal vein catheterized rats. NoAb BioDiscoveries is committed to using innovation to improve the future of drug discovery research and in doing so, consistently develops advanced research tools that better characterize the pharmacokinetics properties of new drug candidates, optimizing the selection of viable clinical candidates. Examples of such advanced protocols include the specialized preclinical pharmacokinetics techniques available at www.noabbiodiscoveries.com: microdialysis and serial collection of plasma and cerebrospinal fluid (CSF) from freely moving rats. These two techniques are used to monitor the concentrations of new drug candidates intended to treat neurological or psychiatric disorders, in the central nervous system (CNS).
Although in vitro ADME assays provide valuable information for the selection of lead compounds, drug discovery research still requires preclinical pharmacokinetics studies to be carried out in order to interpret and extrapolate the information generated by in vitro ADME profiling to in vivo situations. NoAb BioDiscoveries is your one stop research facility for complete drug discovery services that achieve success and accelerate the timelines needed in the production of optimal and viable clinical candidates. With the complete and innovative range of proprietary and specialized services from NoAb BioDiscoveries, you can stay ahead of the competition while reducing the cost associated with identifying and marketing new drugs. NoAb BioDiscoveries has helped to shape and optimize the drug discovery process so that you can consistently maximize success using the timely, accurate and reliable results generated from its superior scientific procedures. NoAb BioDiscoveries will be your trusted partner when you need cutting edge drug discovery services!
